We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

28 hedge funds and large institutions have $6.12M invested in Aevi Genomic Medicine Inc in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

646% more capital invested

Capital invested by funds: $820K → $6.12M (+$5.3M)

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

12% more funds holding

Funds holding: 25 → 28 (+3)

Holders
28
Holders Change
+3
Holders Change %
+12%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$30.5K
2
JC
JBF Capital
Colorado
+$25.6K
3
UBS Group
UBS Group
Switzerland
+$17.6K
4
LTFS
Ladenburg Thalmann Financial Services
Florida
+$14.6K
5
VF
Virtu Financial
New York
+$11.2K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$65.8K
2
Citadel Advisors
Citadel Advisors
Florida
-$24K
3
BC
Birchview Capital
Vermont
-$19K
4
Barclays
Barclays
United Kingdom
-$2
Name Holding Trade Value Shares
Change 		Change in
Stake
AMCA
1
Arthur M. Cohen & Associates
Illinois
$5.33M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$382K +$30.5K +223,844 +9%
Vanguard Group
3
Vanguard Group
Pennsylvania
$156K -$65.8K -482,685 -31%
BlackRock
4
BlackRock
New York
$100K +$53 +387 +0.1%
UBS Group
5
UBS Group
Switzerland
$29K +$17.6K +129,287 +186%
JC
6
JBF Capital
Colorado
$27K +$25.6K +187,945 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$24K – – –
VF
8
Virtu Financial
New York
$24K +$11.2K +82,103 +103%
LTFS
9
Ladenburg Thalmann Financial Services
Florida
$17K +$14.6K +107,000 +1,740%
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$7K – – –
Northern Trust
11
Northern Trust
Illinois
$7K – – –
VAM
12
Verity Asset Management
North Carolina
$4K +$1.84K +13,500 +79%
Bank of America
13
Bank of America
North Carolina
$4K +$3.51K +25,739 +2,574%
State Street
14
State Street
Massachusetts
$3K – – –
DAS
15
Dynamic Advisor Solutions
Arizona
$2K – – –
OIA
16
OneDigital Investment Advisors
Kansas
$2K – – –
Wells Fargo
17
Wells Fargo
California
$2K – – –
MWP
18
MYCIO Wealth Partners
Pennsylvania
$1K – – –
WQ
19
Wealth Quarterback
New Jersey
$10 +$10 +70 New
BNP Paribas Financial Markets
20
BNP Paribas Financial Markets
France
$1 – +2 +100%
Citadel Advisors
21
Citadel Advisors
Florida
– -$24K -160,264 Closed
BC
22
Birchview Capital
Vermont
– -$19K -128,000 Closed
Barclays
23
Barclays
United Kingdom
– -$2 -17 -11%
Simplex Trading
24
Simplex Trading
Illinois
– +$14 +100 New
RWB
25
RMR Wealth Builders
New Jersey
– +$34 +250 New
1
2

GNMX Hedge Fund Activity: Q4 2019 in Review

28 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2019, worth a combined $6.12M — up 646% from $820K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GNMX positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $30.5K. The largest seller was Vanguard Group, cutting an estimated $65.8K.

  • 28 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2019, up from 25 in Q3 2019.
  • Funds reported $6.12M of Aevi Genomic Medicine Inc stock for Q4 2019, up 646% quarter-over-quarter.
  • 5 funds opened new Aevi Genomic Medicine Inc positions in Q4 2019 and 2 closed out, a net change of +3 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2019 was Renaissance Technologies, an estimated $30.5K added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2019 was Vanguard Group, an estimated $65.8K sold.

Based on aggregated 13F filings for Q4 2019.